General MedicationsORALStandard
TAGRISSO
OSIMERTINIB MESYLATE
Standard Dose
EQ 80MG BASE
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Prescription
Summary
Approval overview TAGRISSO is listed in Drugs@FDA under application 208065 (NDA).
Review priority: PRIORITY Marketing status: Prescription Active ingredient OSIMERTINIB MESYLATE Form and strength TABLET;ORAL - EQ 80MG BASE Sponsor ASTRAZENECA Submission history Latest submission status date: 2024-09-25 00:00:00.
Structured Monograph
Clinical summary
Approval overview TAGRISSO is listed in Drugs@FDA under application 208065 (NDA). Review priority: PRIORITY Marketing status: Prescription Active ingredient OSIMERTINIB MESYLATE Form and strength TABLET;ORAL - EQ 80MG BASE Sponsor ASTRAZENECA Submission history Latest submission status date: 2024-09-25 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: PRIORITY
Interaction Notes
- No interaction notes stored yet.